ReviewBiomolecules2019
Creatine for the Treatment of Depression.
Review in Biomolecules, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 4 syntheses or guidelines pooled it, 69 citations in OpenAlex.
- Mitochondrial-inflammation crosstalk in major depressive disorder: molecular mechanisms and therapeutic implications.Molecular psychiatry · 2026Pooled it
- Adaptogens on Depression-Related Outcomes: A Systematic Integrative Review and Rationale of Synergism with Physical Activity.International journal of environmental research and public health · 2023Pooled it
- Creatine in Health and Disease.Nutrients · 2021Pooled it
- Differential and spatial expression meta-analysis of genes identified in genome-wide association studies of depression.Translational psychiatry · 2021Pooled it
- Effects of creatine supplementation with and without exercise and diet intervention on body composition, cognitive function, and markers of health in middle-aged and older adults.Journal of the International Society of Sports Nutrition · 2026Trial
- Single-Dose Creatine Reduces Sleep Deprivation-Induced Deterioration in Cognitive Performance.Nutrients · 2026Trial
- Trial
- Discovery of urinary metabolite biomarkers of psychiatric disorders using two-sample Mendelian randomization.BMC psychiatry · 2026Article
- The role of brain creatine in behavioral health conditions.Frontiers in psychiatry · 2025Review
- Creatine supplementation is safe, beneficial throughout the lifespan, and should not be restricted.Frontiers in nutrition · 2025Article
- Creatine Supplementation in Depression: A Review of Mechanisms, Efficacy, Clinical Outcomes, and Future Directions.Cureus · 2024Review
- Review
- Mitochondria in depression: The dysfunction of mitochondrial energy metabolism and quality control systems.CNS neuroscience & therapeutics · 2024Review
- The major biogenic amine metabolites in mood disorders.Frontiers in psychiatry · 2024Review
- Roles of Nutrients in the Brain Development, Cognitive Function, and Mood of Dogs and Cats.Advances in experimental medicine and biology · 2024Article
- "Heads Up" for Creatine Supplementation and its Potential Applications for Brain Health and Function.Sports medicine (Auckland, N.Z.) · 2023Review
- Novel drug developmental strategies for treatment-resistant depression.British journal of pharmacology · 2022Review
- Review
- Role of Creatine Supplementation in Conditions Involving Mitochondrial Dysfunction: A Narrative Review.Nutrients · 2022Review
- Effects of Creatine Supplementation and Progressive Resistance Training in Stroke Survivors.International journal of exercise science · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Depressed mood, which can occur in the context of major depressive disorder, bipolar disorder, and other conditions, represents a serious threat to public health and wellness. Conventional treatments are not effective for a significant proportion of patients and interventions that are often beneficial for treatment-refractory depression are not widely available. There is, therefore, an immense need to identify novel antidepressant strategies, particularly strategies that target physiological pathways that are distinct from those addressed by conventional treatments. There is growing evidence from human neuroimaging, genetics, epidemiology, and animal studies that disruptions in brain energy production, storage, and utilization are implicated in the development and maintenance of depression. Creatine, a widely available nutritional supplement, has the potential to improve these disruptions in some patients, and early clinical trials indicate that it may have efficacy as an antidepressant agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.